Roche drops hep B antiviral as late-stage pipeline tests 'largely on track' despite COVID-19 disruption

Roche has canned a phase 1 test of a potential hepatitis B antiviral as part of its third-quarter clean-up of unwanted pipeline drugs. In its second-quarter/half-year financials posted Thursday morning, Roche said simply that the drug, RG6217, had been “removed” from phase 1, which in pharma parlance means culled.